Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

lannett company, inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 125 ug - heart failure: digoxin is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. atrial fibrillation: digoxin is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation. digitalis glycosides are contraindicated in patients with ventricular fibrillation or in patients with a known hypersensitivity to digoxin. a hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

novitium pharma llc - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin oral solution usp is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by increased exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. digoxin is indicated to increase myocardial contractility in pediatric patients with heart failure. digoxin oral solution usp is indicated for the control of resting ventricular response rate in patients with chronic atrial fibrillation. digoxin should not be used for the treatment of multifocal atrial tachycardia. allergy to digoxin is rare. digoxin is contraindicated in patients with a known hypersensitivity to digoxin or other forms of digitalis. digitalis glycosides, such as digoxin, are contraindicated

Australija - anglų - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - esmolol hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium acetate trihydrate; glacial acetic acid; hydrochloric acid; water for injections; sodium hydroxide; sodium chloride - supraventricular tachycardia - esmolol noridem is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol noridem is also indicated in non-compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. esmolol noridem is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - esmolol hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; sodium chloride; glacial acetic acid; sodium acetate trihydrate - supraventricular tachycardia,esmolol juno is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol juno is also indicated in non compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. esmolol juno is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 0.5 ml - injection, solution - excipient ingredients: - revestive is indicated for the treatment of adult and paediatric patients 2 years of age and above with short bowel syndrome (sbs) who are dependent on parenteral support.,patients should be stable for at least 4 weeks on their parenteral support regimen before initiating teduglutide therapy

Australija - anglų - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: water for injections - ephedrine hydrochloride injection is indicated in the treatment of hypotension secondary to spinal anaesthesia.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

cardinal health - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 250 ug in 1 ml

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin is indicated for the treatment of mild to moderate heart failure in adults. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ace) inhibitor. digoxin increases myocardial contractility in pediatric patients with heart failure. digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. digoxin is contraindicated in patients with: - ventricular fibrillation [see warnings and precautions ( 5.1)] - known hypersensitivity to digoxin (reactions seen include unexplained rash, swelling of the mouth, lips or throat or a difficulty in breathing). a hypersensitivity reaction to

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin is indicated for the treatment of mild to moderate heart failure in adults. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ace) inhibitor. digoxin increases myocardial contractility in pediatric patients with heart failure. digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. digoxin is contraindicated in patients with: - ventricular fibrillation [see warnings and precautions ( 5.1)] - known hypersensitivity to digoxin (reactions seen include unexplained rash, swelling of the mouth, lips or throat or a difficulty in breathing). a hypersensitivity reaction to

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

remedyrepack inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin tablets, usp are indicated for the treatment of mild to moderate heart failure in adults. digoxin tablets, usp increase left ventricular ejection fraction and improve heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin tablets, usp should be used in combination with a diuretic and an angiotensin-converting enzyme (ace) inhibitor. digoxin tablets, usp increase myocardial contractility in pediatric patients with heart failure. digoxin tablets, usp are indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. digoxin tablets are contraindicated in patients with: - ventricular fibrillation [see warnings and precautions (5.1)] - known hypersensitivity to digoxin (reactions seen include unexplained rash, swelling of the mouth, lips or throat or a difficulty in breathing). a hyper